Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden
CONCLUSION: 1,310 men were treated with abiraterone and 3,579 with enzalutamide. In multivariable analysis, CVD risk was increased in men on abiraterone (hazard ratio (HR): 1.19; 95% confidence interval (CI): 1.03-1.38) and in men on enzalutamide (HR: 1.10; 95% CI: 1.01-1.20). Men with a recent CVD (<12 months) including both men on ART as well as comparators had a much higher probability of a new CVD vs men with no prior CVD. CVD risk was mildly increased in men with PCa on GnRH plus abiraterone or enzalutamide vs comparator men on GnRH. Residual confounding and detection bias may at least partly explain this association.PMID:33606571 | DOI:10.1080/0284186X.2021.1885058
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Gincy George Hanna Vikman Rolf Gedeborg Ingela Franck Lissbrant Hans Garmo Johan Styrke Mieke Van Hemelrijck P är Stattin Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Cholesterol | Databases & Libraries | Education | Heart | Hormones | Insulin | Prostate Cancer | Statin Therapy | Study | Sweden Health | Universities & Medical Training